期刊文献+

长链非编码RNA-肺腺癌转移相关转录子1调控食管癌EC-109细胞侵袭转移的机制 被引量:12

Mechanism of long non-coding RNA-metastasis associated lung adenocarcinoma transcript 1 induced invasion and metastasis of esophageal cancer cell EC-109
原文传递
导出
摘要 目的观察长链非编码RNA-肺腺癌转移相关转录子1(LncRNA-MALAT1)对食管癌细胞EC-109侵袭和转移的影响,并探讨其可能的作用机制。方法应用慢病毒载体shRNA对照、shRNA-MALAT1转染EC-109细胞,采用实时荧光定量PCR法检测EC-109细胞中LncRNA-MALAT1、miR-200a、ZEB1和ZEB2 mRNA的表达;采用细胞侵袭实验检测EC-109细胞的侵袭能力;采用免疫荧光、Western blot法检测EC-109细胞中上皮间质转化(EMT)信号通路相关蛋白的表达;采用双荧光素酶报告基因实验检测EC-109细胞中MALAT1与miR-200a表达的关系。结果实时荧光定量PCR检测结果显示,未转染组、转染shRNA对照组和转染shRNA-MALAT1组EC-109细胞中MALAT1 mRNA的相对表达量分别为1.00、0.97±0.08和0.43±0.06,转染shRNA-MALAT1组EC-109细胞中MALAT1 mRNA的表达明显降低(P〈0.01)。未转染组、转染shRNA对照组和转染shRNA-MALAT1组EC-109细胞中ZEB1 mRNA的相对表达量分别为1.00、1.06±0.07和0.64±0.04,ZEB2 mRNA的相对表达量分别为1.00、0.98±0.05和0.51±0.04,转染shRNA-MALAT1组EC-109细胞中ZEB1和ZEB2 mRNA的相对表达量均明显降低(均P〈0.05)。转染shRNA-MALAT1组的EC-109细胞的穿膜细胞数为(96.81±10.43)个/低倍视野,与转染shRNA对照组EC-109细胞的穿膜细胞数[(278.44±13.28)个/低倍视野]比较,差异有统计学意义(P〈0.01)。免疫荧光和Western blot法检测结果显示,沉默EC-109细胞中MALAT1基因的表达可下调EMT信号通路相关蛋白的表达。双荧光素酶报告基因实验结果显示,与转染miRNA阴性对照组比较,共转染pmirGLO-MALAT1-wt和miR-200a模拟物可明显减少EC-109细胞的荧光素酶活性,而共转染pmirGLO-MALAT1-mut和miR-200a模拟物不能抑制EC-109细胞的荧光素酶活性。结论LncRNA-MALAT1可能作为竞争性内源RNA,竞争性结合miR-200a,从而上调EC-109细胞中ZEB1和ZEB2的表达,促进EMT进程,导致食管癌的侵袭和转移。 ObjectiveTo investigate the effect and mechanism of long non-coding RNA-metastasis associated lung adenocarcinoma transcript 1, (LncRNA-MALAT1) on invasion and metastasis of esophageal cancer cell EC-109.MethodsEC-109 cells were transfected with lentiviral vector carrying short hairpin RNA of MALAT1( shRNA-MALAT1) or a nonspecific shRNA control (shRNA-control). The expressions of MALAT1, microRNA-200a, ZEB1 and ZEB2 were detected by qRT-PCR. The effect of shRNA-MALAT1 on invasion of EC-109 cells was determined by transwell assay. The expressions of components of epithelial-msenchymal transition pathway in EC-109 cells were determined by immunofluorescence array and western blotting. The expression relationship between MALAT1 and miR-200a in EC-109 cells was detected by dual-luciferase reporter assay.ResultsThe result of qRT-PCR showed that the expressions levels of MALAT1, ZEB1 and ZEB2 in shRNA-MALAT1 group were 0.43±0.06, 0.64±0.04 and 0.51±0.04, respectively, significantly lower than 0.97±0.08, 1.06±0.07 and 0.98±0.05 in shRNA-control group and 1 in control group, respectively(all P〈0.05). Transwell assay showed that the number of invaded cells in shRNA MALAT1 group was (96.81±10.43) per low-power field, markedly lower than that of (278.44±13.28) per low-power field in shRNA-control group (P〈0.01). Immunofluorescence staining and Western blotting showed that MALAT1 downregulation significantly reduced the expressions of proteins related to EMT signal pathway in EC-109 cells.Dual luciferase reporter assay showed that compared to negative control, the activities of luciferase reporter in EC-109 cells co-transfected with pmirGLO-MALAT1-wt and miR-200a were significantly down-regulated. While co-transfected pmirGLO-MALAT1-mut with miR-200a mimics had no effect on the luciferase reporter activities of MALAT1.ConclusionLncRNA MALAT1 functions as a competing endogenous RNA to regulate the expressions of ZEB1 and ZEB2 by sponging miR-200a and promotes invasion and migration of esophageal cancer cells through inducing epithelial-mesenchymal transition.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2017年第6期405-411,共7页 Chinese Journal of Oncology
基金 国家自然科学基金(81503414)
关键词 食管肿瘤 长链非编码RNA 微小RNA 肺腺癌转移相关转录子1 上皮间质转化 侵袭 Esophageal neoplasms Long non-coding RNA MicroRNA MALAT1 Epithelial-mesenchymal transition, EMT Invasion
  • 相关文献

参考文献3

二级参考文献33

  • 1郭洪波,于金明,张百江,朱慧,张为迪,黄勇,付政.^(18)FDG PET/CT在术前检测食管癌淋巴结转移及分期中的应用[J].中华胸心血管外科杂志,2006,22(1):28-31. 被引量:16
  • 2Zhou C,Wu YL, Chen (;,el al. Krlolinib versus chemotheraj^y asfirst-line Ireatmenl for palients with advanced EGFK mutation-positive non-small-cell lung rancer ( OPTIMAL, CT()N(i-0802):a nmllicentre, open-lahel, randomised, phase 3 study[ J] . I-am.elOiuol, 2011, 12(8) :735-742.
  • 3Jackman I),Pao Vt , Kiely (;J, el al. Clinical definition of a(.qiiimli-esislance to epidentud growth factor receptor tyrosine kinaseinhibitors in non-small-cell lung can(*er[ J] . J Clin Oncol, 2010,28(2):357-360.
  • 4Li D, Ambiogio L,Shimamura T,et al. BIBW29S2, an irreversibleEGFR/HER2 inhibitor highly effective in preclinical lung cancermodels[J]. Oncogene, 2008, 27(34) :4702-4711.
  • 5Yamada T, Matsumoto K, Wang W, et al. Hepatocyte growth factorreduces susceptibility to an irreversible epidermal growth factorreceptor inhibitor in EGFR-T790M mutant lung cancer[ J].ClinCancer Res, 2010,16( 1) : 174-183.
  • 6Yin PH, Liu X,Qiu YY, et al. Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers : new hope forcancer patients [ J ]. Asian Pac J Cancer Prev, 2012, 13(11):5339-5343.
  • 7Xie XB,Yin JQ,Wen LL, et al. Critical role of heat shock protein 27in bufalin-induced apoptosis in human osteosarcomas : a proteomic-based research[J]. PLoS One, 2012,7( 10) :e47375.
  • 8Kang XH, Xu ZY, Gong YB, et al. Bufalin Reverses HGF-InducedResistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells viaBlockage of Met/PI3k/Akt Pathway and Induction of Apoptosis[J] .Evid Based Complement Altemat Med, 2013, 2013:243859.
  • 9Suda K, TomizawaK,Mitsud(.ni T. Biological and clinical significance ofKRAS mutations in lung cancer : an oncogenic driver that contrastswith EGFR mutation[J], Cancer Metastasis Rev, 2010, 29(1):49-60.
  • 10Solca F, Dahl G, Zoephel A, et al. Target binding properties andcellular activity of afatinib ( BIBW 2992 ),an irreversible ErbBfamily blocker[ J]. J Pharmacol Exp Ther,2012,343 ( 2) : 342-350.

共引文献23

同被引文献27

引证文献12

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部